Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients

Novo Nordisk A/S10 enrolled

Overview

The trial is conducted in North America. The aim of the trial is to assess the safety of turoctocog alfa under conditions of routine clinical care in patients with haemophilia A in Mexico

Study Type

OBSERVATIONAL

Enrollment

Conditions

Congenital Bleeding Disorder Haemophilia A

Interventions

turoctocog alfaDRUG

Patients will be treated with commercially available turoctocog alfa according to local clinical practice at the discretion of the physician

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) * Male and female patients with haemophilia A * Age range is 0 years and above * The decision to initiate treatment with commercially available turoctocog alfa has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study Exclusion Criteria: * Previous participation in this study. Participation is defined as having given informed consent in this study * Known or suspected allergy to turoctocog alfa or related products * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Locations (1)

Novo Nordisk Investigational Site

Monterrey, Nuevo León, Mexico